Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Joseph Scandura

Joseph Scandura

MD, PhD

Weill Cornell Medicine

The risk and management of pulmonary hypertension in patients with polycythemia vera

The risk and management of pulmonary hypertension in patients with polycythemia vera

Joseph Scandura • 10 Sep 2025

Neutrophil-to-lymphocyte ratio: a potential dynamic biomarker of treatment response in PV

Neutrophil-to-lymphocyte ratio: a potential dynamic biomarker of treatment response in PV

Joseph Scandura • 3 Sep 2025

Satiety inhibition in MPNs: the effect of JAKi treatment on leptin levels and body weight

Satiety inhibition in MPNs: the effect of JAKi treatment on leptin levels and body weight

Joseph Scandura • 27 Aug 2025

Translational aspects of MPNs: investigating disease biology

Translational aspects of MPNs: investigating disease biology

Joseph Scandura • 29 Aug 2024

MPN disease biology: JAK2.V617F causes lymphopenia by blocking lymphopoiesis

MPN disease biology: JAK2.V617F causes lymphopenia by blocking lymphopoiesis

Joseph Scandura • 29 Aug 2024

Are thrombotic risk and progression in ET predictable?

Are thrombotic risk and progression in ET predictable?

Joseph Scandura • 25 Aug 2024

Changing clinical trial endpoints in MPNs & the link between hematopoietic fitness and outcomes

Changing clinical trial endpoints in MPNs & the link between hematopoietic fitness and outcomes

Joseph Scandura • 15 Nov 2022

The role of BMT & clinical trials in patients with PV with multiple treatment-limiting toxicities

The role of BMT & clinical trials in patients with PV with multiple treatment-limiting toxicities

Joseph Scandura • 15 Nov 2022

The central role of megakaryocytes in MPN pathophysiology

The central role of megakaryocytes in MPN pathophysiology

Joseph Scandura • 4 Nov 2022